Company Filing History:
Years Active: 2010
Title: Kerstin Greunke: Innovator in Antibody Technology
Introduction
Kerstin Greunke is a prominent inventor based in Hamburg, Germany. She has made significant contributions to the field of recombinant antibody technology. Her innovative work focuses on developing novel antibody constructs that have potential applications in diagnostics and therapeutics.
Latest Patents
Kerstin Greunke holds a patent for "Bivalent IgY antibody constructs for diagnostic and therapeutic applications." This invention relates to the field of recombinant antibody technology. It provides novel recombinant IgY antibody constructs that display a heterotetrameric or homodimeric format stabilized by disulfide bonds. The constant heavy chain domains C2-C4 are partly or completely of avian origin, while the V, V, C, and C1 domains, as well as the hinge region, may be of avian origin or derived from any other species. This invention allows for the combination of the advantages of IgY antibodies with those of established mammalian monoclonal antibodies. IgY antibody constructs comprising nonglycosylated IgY constant heavy chain domains help reduce unwanted interactions with C-type lectins, such as those found in human sera. Furthermore, chimeric IgY antibodies containing mammalian V, V, C, and C1 domains, along with a mammalian hinge region, provide higher molecular stability than IgY antibodies in acidic conditions, making them especially suited for peroral therapeutic applications.
Career Highlights
Kerstin Greunke is associated with Pls-design GmbH, where she continues to advance her research and development in antibody technology. Her work has garnered attention for its innovative approach and potential impact on medical applications.
Collaborations
Kerstin has collaborated with notable colleagues, including Reinhard Bredehorst and Thomas Grunwald. These collaborations have contributed to the advancement of her research and the development of her patented technologies.
Conclusion
Kerstin Greunke is a trailblazer in the field of antibody technology, with her innovative patent paving the way for future advancements in diagnostics and therapeutics. Her contributions are significant and continue to influence the scientific community.